Articles On Immutep (ASX:IMM)

Immutep, Percheron and PYC feature in clinical trial updates Control Bionics guides to higher revenue, despite ongoing NDIS delays Botanix dispatches its first US prescriptions for its anti-sweat remedy   The year is ending with a bang ra...

Immutep Ltd (ASX:IMM) has reported a small-scale conceptual safety test among 49 patients using flagship drug IMP761 has seen no adverse effects. Despite this, shares were down nearly -3% after twenty minutes of Tuesday trade. The data r...

From artificial intelligence (A.I) to zygotes, the biotech sector this year delivered the A to Z of excitement, intrigue, occasional disappointment and downright disaster. His virtual stethoscope on hand, Dr Boreham was on duty to diagnose...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin An additional news report on the recommendation, valuation, forecast and opinion cha...

Here are 10 stocks rated ‘Strong Buy’ by brokers Mining, biotech and energy stocks top list Life360, West African Resources lead picks   The list of stocks below is compiled based on a report from Commsec, which averages the recommendatio...

S&P/ASX 300 Index (ASX: XKO) healthcare stock Immutep Ltd (ASX: IMM) is charging higher today. Shares in the clinical-stage biotech company closed yesterday trading for 35.5 cents. In earlier trade, shares were changing hands for 38....

Immutep (ASX:IMM) has announced promising new data from its Phase IIb TACTI-003 trial, presented at the ESMO Immuno-Oncology Congress 2024. The trial combines the company’s lead drug candidate eftilagimod alpha (efti) with Merck & Co’s...

Immutep (ASX:IMM) has announced the initiation of its TACTI-004 Phase III clinical trial, which aims to evaluate the efficacy of its lead immunotherapy candidate, eftilagimod alfa ("efti"), in treating first-line metastatic non-small cell l...

ASX All Ords stock Immutep Ltd (ASX: IMM) has underperformed the All Ordinaries Index (ASX: XAO) this past year. Over the last 12 months, Immutep shares have gained just under 5%. That compares to an almost 18% gain posted by the All Ords o...

The ASX 200 is expected to dip into the red this Friday, with futures down 0.27% as the booming 2024 Santa rally faces its first early trough. Part of the reason for red tickers across the Aussie bourse in Friday futures was a pause on W...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

  Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt reflects on a year marked by promising clinical trial results and a landmark partnership with Merck. He highlights progress in developing treatments for autoimmune diseases a...

Immutep Ltd (ASX: IMM) shares ended the week on a disappointing note. The small cap ASX biotechnology share fell 3% to finish the session at 33 cents. But its shares may not be trading at those levels for long if one leading broker is to be...

ASX up, Xero leads gains Miners hit as iron ore drops, Variscan jumps 50pc Asian stocks down, Bitcoin hits US$93k before retreating   Aussie shares climbed higher on Thursday, powered by a rally in tech companies and the big banks. At the...

Immutep (ASX: IMM) has presented new data from a Phase II investigator-initiated trial of eftilagimod alpha (efti) in combination with radiotherapy plus Keytruda (pembrolizumab) for patients with soft tissue sarcoma (STS). Based on prelimin...

Three ASX healthcare shares are making their shareholders very happy today, posting gains of 5%, 12% and 19% respectively in morning trade. And this strong performance comes despite some broader healthcare sector headwinds on Thursday, whic...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Rudi Filapek-Vandyck In this week's Weekly Insights:-Mate, Where Have The Profits Gone?-Al...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

Immutep (ASX:IMM) has released its annual report, detailing significant progress over the past year with its lead immunotherapy candidate eftilagimod alpha (efti). This drug is designed to activate the body’s immune system to better recogni...

  To register for Friday's webinar click here. Immutep Limited (ASX:IMM) has fully recruited participants for Part A of its Phase I study evaluating IMP761, a novel LAG-3 immunotherapy. The single-dose, placebo-controlled trial has been com...

With the gold price trading around record highs, a number of ASX 200 gold shares have been rallying strongly this year. This has seen the S&P/ASX All Ordinaries Gold index rise 22% since the start of the year. But if you thought you wer...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

Cettire Ltd (ASX: CTT) shares are catching the eye with a very strong gain on Tuesday. At the time of writing, the ASX All Ordinaries stock is up 48% to $1.98. Though, the online luxury products retailer's shares remain down by 60% from the...

Biotech company Immutep Ltd (ASX:IMM) has received a R&D Tax Incentive of around A$3.6 million from the French Government to boost development of two current product candidates. The incentive – worth €2,194,918 – was provided under t...

The ASX200 is expected to open 0.12% lower today, despite strong gains on Wall Street. Investors in Australia are awaiting the Reserve Bank of Australia's (RBA) announcement on interest rates, with a decision due later today.   In the U.S....

The ASX200 is set to open 0.12% lower today, despite strong performances on Wall Street, as Australian investors await a rate cut decision from the Reserve Bank (RBA) later today. In the US, all three major bourses were higher: the S&amp...

  Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses the company's latest results in head and neck cancer. Peter Milios: I'm Peter Milios from the Finance News Network, and today we're talking with Immutep (ASX:IMM)....

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record another gain. At the time of writing, the benchmark index is up 0.2% to 8,135.1 points. Four ASX shares that are failing to follow the market higher today are...

Good afternoon. The ASX200 has been up 0.42% at 8,134 points. The local bourse is very close to breaking its record of 8,148 set in August. The Aussie market has so far shrugged of a second assassination attempt on former President Trump...

‘Wheezo’ maker Respiri says a new US deal will help to propel the company to cash-flow break even by the end of the year Immutep reports further promising data from its head neck and shoulder cancer program Oncosil Medical targets the diff...

  Immutep (ASX:IMM) has reported that eftilagimod alpha (efti) combined with MSD's KEYTRUDA® shows high efficacy and a favourable safety profile for treating head and neck cancer. The TACTI-003 trial revealed a 31.0% overall response rate i...

ASX nears record high as Fed rate cut speculation grows Wall Street rallies ahead of Fed decision; Boeing and Adobe shares slide Another Donald Trump’s assassination attempt in the past few hours?   The ASX could hit a new all-time high o...

Copper stocks elevated to the S&P/ASX 200 and S&P/ASX 300 including Sandfire Resources and Capstone Copper Corp Radiopharmaceutical company Clarity Pharmaceuticals is among healthcare names elevated to the S&P/ASX 300 Newly lis...

Dimerix chief Dr Nina Webster describes the three stages of drug development and the hurdles involved Dimerix is in phase III trials to treat a rare kidney condition Following promising interim analysis, further results are expected in mid...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

Inoviq’s NEURO-NET validated for Parkinson’s disease Nyrada’s NYR-BI03 shows safety in rats; Phase I planned for late 2024 Immutep at ESMO: data on eftilagimod alpha will be presented   Inoviq’s NEURO-NET validated in Parkinson’s Inoviq (...

  Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses progress with the company's IMP761 drug, which is potentially active in more than 90% of autoimmune diseases. Peter Milios: I'm Peter Milios from the Finance News N...

  To register for Friday's webinar click here. Immutep (ASX:IMM) has initiated a Phase I clinical trial to evaluate the safety and efficacy of IMP761, a novel LAG-3 agonist antibody. IMP761 is designed to restore immune system balance by en...

In a potential game-changer for millions of people worldwide, Immutep (ASX:IMM; NASDAQ:IMMP) has initiated the first human trials of IMP761, a novel agonist LAG-3 antibody designed to treat autoimmune diseases. The commencement of this Phas...

ASX set to open higher, driven by easing inflation data in the US US PPI fell short of expectations, boosting hopes for a Fed rate cut Starbucks up 24pc, Nvidia up 7pc, and Avon filed for bankruptcy   The ASX is set to open sharply higher...

Immutep (ASX:IMM) has confirmed it’s dosed the first human patient with its LAG-3 based autoimmune drug candidate IMP761. LAG-3 – which stands for Lymphocyte Activation Gene 3 – is believed to be able to interfere with haywire T cells in...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

The S&P/ASX 200 Index (ASX: XJO) endured a tough start to the trading week this Monday, continuing the market malaise we saw at the end of last week's trading. By the closing bell today, the A...

While the S&P/ASX 200 Index (ASX: XJO) faces a downturn, slipping 0.9% to 7,902.4 points, several ASX shares have managed to buck the trend and achieve impressive gains.  29Metals Ltd (ASX: 29M) stands out with its share price climbing...

ASX healthcare stock Immutep Ltd (ASX: IMM) is surging after the company released a market-sensitive announcement before the open on Monday. Immutep advised it had a successful meeting with the US Food and Drug Administration (FDA) regar...

Immutep receives FDA feedback for its TACTI-004 Phase III trial design for tackling non small-cell lung cancer Althea forms JV to enter the US cannabis beverage market Chimeric enrols first participant in a Phase 1/2 trial for its CHM CDH1...

Two S&P/ASX 200 Index (ASX: XJO) shares are managing to swim against the retreating tide today. At the time of writing, the benchmark Aussie index is down 0.8%, with many stocks catching headwinds out of both the United States and Chin...

The S&P/ASX 200 Index (ASX: XJO) is having a tough time on Monday. In afternoon trade, the benchmark index is down 0.9% to 7,902.4 points. Four ASX shares that are not letting that hold them back are listed below. Here's why they are ri...

Immutep (ASX:IMM; NASDAQ:IMMP), a leading biotechnology firm specialising in LAG-3 immunotherapy, has achieved a significant milestone in its quest to redefine cancer treatment. Today, the company announced positive feedback from the US Foo...